Subject category:
Strategy and General Management
Published by:
IBS Case Development Center
Length: 13 pages
Data source: Published sources
Topics:
Amgen's growth strategies; Biotechnology industry; Research and development (R&D); Genentech, Chiron Corporation, Biogen; Patent expiries; American pharmaceutical industry; Roger M Perlmutter; Kevin W Sharer; United States Food and Drug Administration; Generic competition; Mergers & acquisitions (M&A); Immunex Corporation; Joint ventures; Epogen, Enbrel, Aranesp, Erythropoietin, Johnson and Johnson
Share a link:
https://casecent.re/p/19854
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
Amgen, one of the world''s leading biotechnology companies, had sales of US$8.4 billion in 2003. Though the sales and profits of the company were higher than its competitors, it was lagging behind on the innovation front. Over the years the company grew with several mergers and acquisitions. It expected to achieve a turnover of US$10 billion in 2004 and promised investors a 20% growth rate untill 2005. The case offers rich insights into Amgen''s growth strategies and the way it intends to achieve the promised growth.
About
Abstract
Amgen, one of the world''s leading biotechnology companies, had sales of US$8.4 billion in 2003. Though the sales and profits of the company were higher than its competitors, it was lagging behind on the innovation front. Over the years the company grew with several mergers and acquisitions. It expected to achieve a turnover of US$10 billion in 2004 and promised investors a 20% growth rate untill 2005. The case offers rich insights into Amgen''s growth strategies and the way it intends to achieve the promised growth.